

Parvovirus B19 Quantitative Real-time DNA PCR

Test ID	1500 Parvovirus B19 Real-time qPCR
Clinical Utility	Parvovirus B19 manifests itself as an acute or chronic hematological disorder in immunocompromised patients. It can cause persistent anemia, sometimes associated with leukopenia and thrombocytopenia. Pediatric transplant patients are at risk for chronic infections, which can be associated with lung and/or renal disorders. Quantitative DNA PCR can be used to detect the presence of the virus, track the course of infection, and monitor response to treatment.
Procedure	Extraction of parvovirus B19 viral DNA from plasma, bone marrow, biological fluids, or tissues; amplification and detection using real-time, quantitative PCR. An internal control is added to ensure the extraction was performed correctly and the PCR reaction was not inhibited.
Specimens	Whole Blood: 3-5 ml submitted in an EDTA tube; ship ambient. CSF: 1 ml fluid frozen; submitted in a sterile, leakproof tube; ship on dry ice. Amniotic Fluid: 1-4 ml submitted in a sterile, leakproof tube; ship ambient. Other: Please inquire.
Specificity	The primers and probes used in this assay are specific for parvovirus B19 based on similarity search algorithms. Additionally, no cross reactivity was detected when tested against adenoviruses, BKV, CMV, EBV, HSV-1, HSV-2, HHV-6 variant A, HHV-6 variant B, HHV-7, HHV-8, JCV, SV-40, and VZV.
Assay Range	100 copies/ml to 1×10^{10} copies/ml
Turnaround Time	Within 24 hours of receiving specimen

PCR tests are performed pursuant to a license agreement with Roche Molecular Systems, Inc.

This assay was developed and the performance characteristics were determined at ViraCor Laboratories. This test is performed in a CLIA certified laboratory. FDA approval is not required for the performance of this test.

AS13-0108